CHINA'S drug authority has decided to allocate raw materials to clotting factor VIII producers to ease a nationwide shortage of the factor, which is a plasma-derived protein and a main treatment for hemophilia. The State Food and Drug Administration said that it has asked four blood products companies based in Shanghai, Shandong, He'nan and Guiyang to supply cryoprecipitate to the country's three clotting factor VIII producers as raw materials.